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Abstract
Introduction. Vitamin K antagonists and non-vitamin K antagonist oral anticoagulants (NOAC) are used in the treatment 
of atrial fibrillation for the prevention of thromboembolic events.
Materials and methods. The authors studied 389 patients (45.8% female) with nonvalvular atrial fibrillation, who have 
been taking apixaban (12.6%), dabigatran (38.6%), rivaroxaban (26.7%) and acenocoumarol (22.1%). Creatinine levels 
were controlled after 2, 6 and 12 months. The authors worked out an estimated glomerular filtration rate (eGFR) by 
means of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Results. The changes in creatinine and eGFR values after 2, 6, 12 months in all 4 subgroups were statistically signifi-
cant. Post hoc tests showed changes in creatinine and eGFR values after 2, 6, 12 months for apixaban, dabigatran and 
rivaroxaban compared with acenocoumarol. Three NOACs were associated with ≥ 20% decline in eGFR [hazard ratio 
(HR): 0.24, 95% confidence interval (CI): 0.16–0.37, p < 0.001], ≥ 30% increase in creatinine concentration (HR: 0.19, 
95% CI: 0.11–0.32, p < 0.001) and eGFR < 44 mL/min/1.73 m2 (HR: 0.24, 95% CI: 0.11–0.55, p = 0.002).
Conclusion. Using of NOACs is connected with more positive effects of renal outcomes than treatment with acenoco-
umarol.
Key words: nonvalvular atrial fibrillation, acenocoumarol, non-vitamin K antagonist oral anticoagulants (NOACs), 
estimated glomerular filtration rate (eGFR)
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Introduction
This arrhythmia is widespread cardiac disease. It causes 
the possibility of morbidity and death rate due to some 
thromboembolic incidents. The calculations of all the 
events were based on the CHA2DS2-VASc score [1]. Kidney 
function is significant in the case of people with this arrhyth-
mia, who were given oral anticoagulants since the impair-
ment of their work may contribute to thrombotic diseases 
and bleeding [2]. Clinical trials have shown that vitamin K 
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Results
Mean pre-treatment eGFR in the study group was 67.12 
± 20.41 mL/min per 1.73 m2 and average serum creati-
nine value was 1.08 ± 0.39 mg/dL. The mean eGFR after 
12 months was 67.64 ± 20.59 mL/min per 1.73 m2, whereas 
the average serum creatinine was 1.07 ± 0.37 mg/dL. eGFR 
below 15 mL/min per 1.73 m2 was found in one patient 
(Tables 2–4). The changes in the values of creatinine and 
eGFR were calculated as the creatinine and eGFR levels 
adjusted for baseline levels after 2, 6, 12 months. The 
minimum sample size for each ANOVA Kruskal-Wallis ana-
lysis was estimated using Develve software (the minimum 
sample size for creatinine ANOVA Kruskal-Wallis analysis 
after 2 months equals 49 patients, after 6 months equals 
44 patients, after 12 months equals 20 patients; the mini-
mum sample size for eGFR ANOVA Kruskal-Wallis analysis 
after 2 months equals 26 patients, after 6 months equals 
28 patients, after 12 months equals 13 patients).
The percentage of people being treated by means of 
angiotensin-converting enzyme inhibitors (ACEI), angioten-
sin receptor blockers (ARB), diuretics have been shown 
in Table 1. There hasn’t been any significant difference 
among the number of patients using these drugs and be-
ing exposed to the risk of contrast. It was calculated us-
ing chi-square for multidimensional contingency tables in 
PQSTAT software v 1.6.8. (for ACEI or ARB chi-square sta-
tistic 0.94, p = 0.82; for diuretics (one or more) chi-square 
2.38, p = 0.5; for contrast chi-square 3.77, p = 0.29).
According to Kruskal-Wallis ANOVA analysis, the chang-
es in creatinine values after 2, 6, 12 months in 4 sub-
groups were statistically significant (after 2 months H 
test statistic = 71.64, p < 0.001, after 6 months H test 
statistic = 56.61, p < 0.001 after 12 months H test sta-
tistic = 89.73, p < 0.001). Post hoc tests (Dunn Bonfer-
roni) showed important differences in creatinine values 
after 2 months (for apixaban, dabigatran and rivaroxa-
ban p < 0.001 compared with acenocoumarol), after 
6 months (for apixaban p = 0.001, dabigatran and riva-
roxaban p < 0.001 compared with acenocoumarol), af-
ter 12 months (for apixaban, rivaroxaban and dabigatran 
p < 0.001). According to Kruskal-Wallis ANOVA analysis, 
the changes in eGFR values after 2, 6, 12 months in 4 sub-
groups were statistically significant (after 2 months H sta-
tistical test = 76.36, p < 0.001, after 6 months H test sta-
tistic = 54.04; p < 0.001, after 12 months H statistical 
test = 99.00, p < 0.001). Post hoc tests (Dunn Bonferroni) 
showed changes in eGFR values after 2 months (for apixa-
ban, dabigatran and rivaroxaban p < 0.001 compared with 
acenocoumarol), after 6 months (for apixaban p = 0.003, 
dabigatran and rivaroxaban p < 0.001 compared with 
acenocoumarol), after 12 months (for apixaban, rivaroxa-
ban and dabigatran p < 0.001) (Figure 1).
antagonists strengthened calcification of most vessels and 
thus have worsened renal function [3]. All non-vitamin K 
antagonist oral anticoagulants (NOACs) have a beneficial 
effect on blood vessels and protect the kidney [4, 5].
We were going to compare the results of various an-
ticoagulants on kidneys in patients with with nonvalvular 
atrial fibrillation (NVAF).
Material and methods
The study was approved by the local ethical committee at 
the University of Lodz in Poland (number RNN/134/18/KE 
of 15th May 2018). Some patients were included retro-
spectively and there was no need for informed consent. 
The remaining patients agreed to the study and telephone 
conversations regarding the values of creatinine if they 
were not hospitalized after the last result.
The authors have included patients with NVAF, who 
started oral anticoagulation from January 2018 to Janu-
ary 2019 and who have been taking NOACs (apixaban, 
dabigatran, rivaroxaban) or acenocoumarol since the be-
ginning of their treatment. The patients were observed for 
one year after starting the therapy. Creatinine levels were 
controlled after 2, 6 and 12 months. The estimated glome-
rular filtration rate (eGFR) was worked out through Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation. People with chronic kidney disease (CKD) were 
not excluded. 389 patients (45.8% female) with NVAF took 
part in the study, who were treated with apixaban (12.6%), 
dabigatran (38.6%), rivaroxaban (26.7%) and acenocou-
marol (22.1%). The research group is presented in Ta-
ble 1. 3 renal outcomes were assessed: ≥ 20% decline 
in eGFR, ≥ 30% increase in serum creatinine and eGFR 
< 44 mL/min/1.73 m2 (excluding patients with baseline 
eGFR < 44 mL/min/1.73 m2).
Statistical analysis
Statistical calculations were performed using Medcalc 
software, PQStat v 1.6.8. and Develve. All parameters 
were shown as average value ± standard deviation (SD). 
4 drugs were studied and 6 pairs of comparisons were 
shown. The authors assumed that changes between the 
groups were significant when the p-value was < 0.05. The 
D’Agostino-Pearson test was used to determine the distribu-
tion. One-way analysis of variance (ANOVA) Kruskal-Wallis 
test was applied to test the change between the average 
differences in creatinine and eGFR values after 2, 6 and 
12 months of 4 subgroups (multiple testing), then Dunn 
Bonferroni post hoc test was used. The minimum sample 
size for each ANOVA Kruskal-Wallis analysis was estimated 
using Develve software. Cox proportional hazard regression 
was calculated to see the differences between the groups 
for all renal outcomes.
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3 NOACs were connected with limited risks of ≥ 20% 
decrease in eGFR [hazard ratio (HR): 0.24; 95% confi-
dence interval (CI) 0.16–0.37, p < 0.001], ≥ 30% increase 
in creatinine concentration (HR: 0.19, 95% CI: 0.11–0.32, 
p < 0.001) and eGFR < 44 mL/min/1.73 m2 (HR: 0.24, 95% 
CI: 0.11–0.55, p = 0.002) with the correction of p-values by 
Dunn Bonferroni tests. Every NOAC and acenocoumarol was 
analysed, NOACs showed smaller risks of ≥ 20% decrease 
in eGFR, ≥ 30% increase in creatinine concentration and 
eGFR < 44 mL/min/1.73 m2 except apixaban (Tables 5–7).









Age, years 69.6 ± 10.3 69.54 ± 10.8 67.33 ± 9.31 67.87 ± 10.3
eGFR [mL/min/1,73 m2] 61.83 ± 22.64 64.84 ± 22.78 74.89 ± 17.24 65.97 ± 18.27
CHA2DS2-VASc 3.6 ± 1.8 3.3 ± 1.6 3.2 ± 1.3 3.2 ± 1.5
Creatinine concentration 1.22 ± 0.48 1.14 ± 0.46 0.95 ± 0.25 1.08 ± 0.34
HAS-BLED 1.9 ± 1.1 1.7 ± 0.9 1.8 ± 1.0 1.6 ± 0.9
Female (N = 178) 21 44 40 73
Medical history
Acetylsalicylic acid treatment 10.2% 10.6% 7.0% 8.7%
Clopidogrel treatment 12.2% 9.6% 4.7% 7.3%
Pulmonary hypertension 8.2% 5.8% 5.8% 3.3%
Hypertension 85.7% 86.5% 75.6% 82.7%
Hyperlipidemia 75.5% 60.6% 48.8% 59.3%
PCI 26.5% 23.1% 12.8% 22.7%
Heart failure 55.1% 49.0% 48.8% 46.0%
Diabetes mellitus 28.6% 36.5% 27.9% 27.3%
Thromboembolism 4.1% 7.7% 16.3% 10.7%
Myocardial infarction 18.4% 18.3% 11.6% 13.3%
Anaemia 14.3% 6.7% 8.1% 4.0%
Kidney disease 36.7% 18.3% 8.1% 10.7%
Obesity 30.6% 26.92% 30.23% 26.67%
Alcoholism 2.0% 1.0% 1.2% 0.7%
Smoking 10.2% 5.8% 4.7% 11.3%
Cardioversion 55.1% 58.7% 41.9% 60.7%
Hyperthyroidism 14.3% 6.7% 8.1% 6.0%
Hypothyroidism 6.1% 9.6% 10.5% 10.7%
Cancer 6.1% 5.7% 4.7% 7.3%
Depression 2.0% 1.9% 0.0% 2.7%
Ablation 26.5% 16.4% 7.0% 30.0%
Pacemaker/ICD 10.2% 22.1% 26.7% 12.7%
Liver disease 4.1% 1.0% 0.0% 1.3%
Peripheral artery disease 0.0% 2.9% 2.3% 0.0%
ACEI or ARB 83.6% 78.9% 83.7% 82.0%
Diuretics (one or more) 65.3% 54.8% 62.8% 56.7%
Contrast 16.3% 6.73% 9.3% 8.7%
Values are mean ± standard deviation or %. Thromboembolism includes ischemic stroke, systemic embolism and transient ischemic attack; eGFR — estimated glomerular rate; CHA2DS2-VASc — congestive 
heart failure, hypertension, age ≥ 75 years, age 65 to 74 years, stroke or transient ischemic attack or thromboembolism, vascular disease, diabetes, sex category (female); HAS-BLED — hypertension, 
 abnormal kidney and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol; PCI — percutaneous coronary intervention; ICD — implantable cardioverter-defibrillator; 
ACEI —angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers
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Discussion
This research proved that NOACs have a less pronoun-
ced effect on kidney function compared to VKA. While 
comparing acenocoumarol with NOACs, new drugs were 
associated with a smaller risk of ≥ 20% decrease in eGFR, 
≥ 30% increase in creatinine concentration and eGFR 
< 44 mL/min/1.73 m2.
Vitamin K antagonists inhibit the synthesis of active 
clotting factors related to vitamin K (II, VII, IX, X). VKAs 
increase vascular calcifications strengthened by inhibition 
of the vitamin K-dependent protein matrix gamma-carboxy-
glutamic acid and activation of the vascular bone morpho-
genetic protein (BMP) signalling pathway [6–8]. An increase 
of osteogenesis and calcium accumulation results from 
increased activation of BMP, their receptors and inhibitor 
Table 2. Mean creatinine values and standard deviations after 2, 6, 12 months








Apixaban 1.22 ± 0.48 1.15 ± 0.46 1.2 ± 0.48 1.19 ± 0.49
Rivaroxaban 1.14 ± 0.46 1.04 ± 0.33 1.07 ± 0.37 1.08 ± 0.43
Acenocumarol 0.95 ± 0.25 1.03 ± 0.26 1.06 ± 0.3 1.16 ± 0.37
Dabigatran 1.08 ± 0.34 0.99 ± 0.25 0.99 ± 0.24 0.97 ± 0.24
Table 3. Chronic kidney disease stages before oral anticoagulation
Stage of renal failure 









G1 7 20 17 19
G2 18 39 52 70
G3a 9 25 13 41
G3b 12 13 4 16
G4 3 6 0 4
G5 0 1 0 0
GFR — glomerular filtration rate
Table 4. Chronic kidney disease stages after 12 months of oral anticoagulation
Stage of renal failure 









G1 4 20 6 30
G2 22 46 44 80
G3a 10 19 19 28
G3b 10 17 15 10
G4 3 2 1 2
G5 0 0 1 0
GFR — glomerular filtration rate
(MPG) [9, 10]. Factor Xa and thrombin contributed to incre-
ased risk of vascular inflammation through thrombin recep-
tor — protease-activated receptor (PAR2) [6]. PAR2 signal-
ling is important in the control of kidney haemodynamics, 
perfusion and rapid vasoconstriction. PAR2 stimulation 
can cause the growth of renal renin activation. PAR2 inhi-
bition may cause decrease activation of interleukin 6 and 
8 and leukocytes. PAR antagonists nephron cells can cau-
se decreased giving off molecules such as transforming 
growth factor β (TGF-β), which may lead to the increase of 
kidney fibrosis and nephritis [11].
Yao et al. [12] assessed four renal outcomes in 2 years: 
≥ 30% decline in eGFR, doubling of the serum creatinine va-
lue, acute kidney injury and kidney failure (eGFR < 15 mL/ 
/min/1,73 m2) and showed that 3 NOACs were connected 
with a lower risk of these four endpoints in comparison with 
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Table 5. Hazard ratios (HR) with 95% confidence interval (CI) with the correction of p values by Bonferroni statistics for risk of ≥ 20% decli-
ne in estimated glomerular filtration rate (eGFR)
Drug Number of incidences HR 95% CI p
Apixaban 11 0.40 0.21–0.79 0.018
Rivaroxaban 12 0.24 0.11–0.38 < 0.001
Dabigatran 18 0.21 0.12–0.37 < 0.001
Acenocoumarol 43 Reference Reference Reference
Table 6. Hazard ratios (HR) with 95% confidence interval (CI) for risk of ≥ 30% increase in creatinine concentration with the correction 
of p values by Bonferroni statistics
Drug Number of incidences HR 95% CI p
Apixaban 7 0.27 0.16–0.82 0.028
Rivaroxaban 5 0.13 0.05–0.30 < 0.001
Dabigatran 11 0.14 0.09–0.36 < 0.001
Acenocoumarol 32 Reference Reference Reference
Table 7. Hazard ratios (HR) with 95% confidence interval (CI) for risk of estimated glomerular filtration rate (eGFR) < 44 mL/min/1.73 m2 
with the correction of p values by Bonferroni statistics
Drug Number of incidences HR 95% CI p
Apixaban 6 0.51 0.2–1.3 0.6
Rivaroxaban 5 0.2 0.07–0.52 0.004
Dabigatran 9 0.24 0.11–0.55 0.002
Acenocoumarol 20 Reference Reference Reference
Figure 1. The changes in creatinine and estimated glomerular filtration rate (eGFR) values: A. The changes in creatinine values after 2 months 
in 4 subgroups (1 — apixaban, 2 — rivaroxaban, 3 — acenocoumarol, 4 — dabigatran); B. The changes in creatinine values after 6 months 
in 4 subgroups; C. The changes in creatinine values after 12 months in 4 subgroups; D. The changes in eGFR values after 2 months in 
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warfarin. During this study, the treatment with NOACs sho-
wed benefits, but they were weaker, which may be related 
to the fact that this study lasted for a year [12]. An intere-
sting analysis by Zhang et al. showed a decreased risk of 
kidney deterioration for NOACs in juxtaposition with VKAs 
or acetylsalicylic acid [13].
Some other research proved that warfarin may cause 
an increased risk of decrease of eGFR than dabigatran in 
the study of RE-LY (Randomized Evaluation of Long-Term 
Anticoagulant Therapy) [2]. Apixaban similarly contributed 
to acute renal failure as warfarin in the ARISTOTLE (Apixa-
ban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation) trial [14].
Another study of NOACs and warfarin confirmed bet-
ter results of therapy for a normal dose of dabigatran in 
patients with correct renal function, whereas a low dose 
of apixaban or dabigatran in 150 mg could be applied in 
nonvascular atrial fibrillation patients with moderate kid-
ney disease [15–17].
The significant changes in kidney function in the 
ptients treated with apixaban or warfarin were not in 
a subanalysis ARISTOTLE. The advantages of apixaban 
versus warfarin on thromboembolic events and serious 
bleeding were shown in patients with adequate or wrong 
kidney haemodynamics [14]. RE-LY and ROCKET AF (Riva-
roxaban Once Daily Oral Direct Factor Xa Inhibition Com-
pared with VItamin K Antagonism for Prevention of Stroke 
and Embolism Trial in Atrial Fibrillation) trials confirmed 
a slower decrease of eGFR with dabigatran and rivaroxa-
ban than with warfarin [6, 18]. The correct renal function 
is significant for people with atrial fibrillation because 
it diminishes the cases of thromboembolic events and 
bleeding [2, 16].
Summing it up, the impact of oral anticoagulants on 
renal function is essential for the effectiveness of this 
treatment. Taking into consideration the values of throm-
boembolic and bleeding cases, one cannot fail to notice 
that these drugs are a good choice compared to VKAs [19].
Conclusion
Therapy with NOACs carries a smaller risk of adverse renal 
outcomes than treatment with acenocoumarol. 3 NOACs 
had decreased risks of ≥ 20% decrease in eGFR, ≥ 30% 
increase in creatinine concentration and eGFR < 44 mL/ 
/min/1.73 m2. When comparing each NOAC with aceno-
coumarol, all NOACs showed fewer risks of ≥ 20% drop in 
eGFR and ≥ 30% increase in creatinine concentration and 
eGFR < 44 mL/min/1.73 m2 except apixaban.
Limitation of study
The presented study lasted only a year and the observed 
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Streszczenie
Wstęp. Antagoniści witaminy K i doustne leki przeciwkrzepliwe niebędące antagonistami witaminy K (NOAC) są 
wykorzystywane w leczeniu migotania przedsionków w prewencji incydentów zakrzepowo-zatorowych.
Materiał i metody. Do badania włączono 389 pacjentów (45,8% kobiet) z niezastawkowym migotaniem przedsionków 
(NVAF), którzy przyjmowali apiksaban (12,6%), dabigatran (38,6%), riwaroksaban (26,7%) i acenokumarol (22,1%). 
Stężenie kreatyniny było kontrolowane po 2, 6 i 12 miesiącach. Oceniono szacowany współczynnik przesączania 
kłębuszkowego (eGFR) za pomocą wzoru Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
Wyniki. Różnice w wartościach kreatyniny i eGFR po 2, 6 i 12 miesiącach w 4 podgrupach były istotne statystycznie. 
Testy post hoc ujawniły różnice w stężeniu kreatyniny i wartości eGFR po 2, 6 i 12 miesiącach w odniesieniu do apik-
sabanu, dabigatranu i riwaroksabanu w porównaniu z acenokumarolem. Stosowanie trzech NOAC było skojarzone z co 
najmniej 20-procentowym spadkiem eGFR (współczynnik ryzyka [HR]: 0,24; 95-proc. przedział ufności [CI]: 0,16–0,37; 
p < 0,001), z co najmniej 30-procentowym wzrostem stężenia kreatyniny (HR: 0,19; 95% CI: 0,11–0,32; p < 0,001) oraz 
z eGFR poniżej 44 ml/min/1,73 m2 (HR: 0,24; 95% CI: 0,11–0,55; p = 0,002).
Wnioski. Zastosowanie NOAC wiąże się z korzystniejszym wpływem na funkcję nerek niż leczenie acenokumarolem.
Słowa kluczowe: niezastawkowe migotanie przedsionków, acenokumarol, doustne leki przeciwkrzepliwe niebędące 
antagonistami witaminy K (NOAC), szacowany współczynnik filtracji kłębuszkowej (eGFR)
Folia Cardiologica 2021; 16, 1: 16–22
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